Vol. 17 No. 3 (2024), AUTOIMMUNE DISEASES
Vol. 17 No. 3 (2024)
AUTOIMMUNE DISEASES

Primary Immune Thrombocytopenia in Children: An Analysis of the Therapy Efficacy in Compliance with the National Clinical Guidelines

Published 01.07.2024
Maksim Yurevich Rykov
Pediatric Regional Clinical Hospital, 23 Stepana Razina nab., Tver, Russian Federation, 170100; Tver State Medical University, 4 Sovetskaya ul., Tver, Russian Federation, 170100
https://orcid.org/0000-0001-9777-1220
M.Yu. Rykov
Russian State Social University, 4 korp. 1, Vilgelma Pika ul., Moscow, Russian Federation, 129226
https://orcid.org/0000-0002-8398-7001
2024-3
PDF_2024-17-3_285-290 (Russian)

Keywords

primary immune thrombocytopenia
clinical guidelines
therapy
children

How to Cite

1.
Rykov M.Y., Rykov M.Y. Primary Immune Thrombocytopenia in Children: An Analysis of the Therapy Efficacy in Compliance with the National Clinical Guidelines. Клиническая онкогематология. 2024;17(3):285-290. doi:10.21320/2500-2139-2024-17-3-285-290
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Keywords

Abstract

AIM. To assess the treatment efficacy in children with primary immune thrombocytopenia (ITP).

MATERIALS & METHODS. The analysis included 13 ITP patients (6 girls and 7 boys) with the mean age of 9.5 years (range 4–17 years) admitted to the Pediatric Hospital of the Tver region in 2023. Primary ITP was preceded by infection in 9 (69 %) children and by measles vaccination in 1 (8 %) child. The mean time after infection onset was 11 days (range 5–15 days). As assessed by the pediatric bleeding score, hemorrhage severity was of grade 1 in 4 (31 %), grade 2 in 3 (23 %), and grade 3 in 6 (46 %) patients. Hematuria was identified in 3 (23 %) patients, and menorrhagia was detected in 1 (8 %) patient. The mean platelet count by the time of admission to the hospital was 9 × 109/L (range 1–86 × 109/L).

RESULTS. The incidence of newly diagnosed primary ITP appeared to be 5.7 cases per 100,000 children in the Tver region. Treatment started with 20 mg/m2 IV dexamethasone on Day 1–3 in 7 (54 %) children, 1000 mg/kg IVIG on Day 1 in 2 (15 %) children, and 2 mg/kg prednisolone per os during 21 days in 1 (8 %) child. Dynamic follow-up was conducted on 3 (23 %) patients. In 2 (17 %) patients, steroid therapy had to be discontinued and IVIG was started due to increased hemorrhage and/or developing corticosteroid complications. Partial and complete responses were achieved in 8 (62 %) and 4 (31 %) patients, respectively. In 1 (8 %) case, the response was not assessed. The overall response rate to the first-line therapy was 92 %. The mean platelet count at hospital discharge was 107 × 109/L (range 20–307 × 109/L), and the mean number of hospital days was 10.2 (range 2–23). The platelet count decrease to grade 1/2 was observed in 3 (23 %) children during the first 6 weeks followed by spontaneous complete recovery during the subsequent 1–2 weeks.

CONCLUSION. The treatment of pediatric primary ITP in full compliance with the National Clinical Guidelines showed very high efficacy in terms of achieving primary response and preventing relapses. The relatively high overall IVIG use rate was accounted for by a slow response to corticosteroids, increased hemorrhage, risk factors, and parental concern.

PDF_2024-17-3_285-290 (Russian)

References

  1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood. 2009;113(11):2386–93. doi: 10.1182/blood-2008-07-162503.
  2. Consolini R, Legitimo A, Caparello MC. The Centenary of Immune Thrombocytopenia – Part 1: Revising Nomenclature and Pathogenesis. Front Pediatr. 2016;4:102. doi: 10.3389/fped.2016.00102.
  3. Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022;76:103820. doi: 10.1016/j.ebiom.2022.103820.
  4. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145(2):235–44. doi: 10.1111/j.1365-2141.2009.07615.x.
  5. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–817. doi: 10.1182/bloodadvances.2019000812.
  6. Heitink-Polle KMJ, Uiterwaal CSPM, Porcelijn L, et al. Intravenous immunoglobulin vs. observation in childhood immune thrombocytopenia: A randomized controlled trial. Blood. 2018;132(9):883–91. doi: 10.1182/blood-2018-02-830844.
  7. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–66. doi: 10.1182/bloodadvances.2019000966.
  8. Bennett CM, Neunert C, Grace RF, et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer. 2018;65(1). doi: 10.1002/pbc.26736.
  9. Hsieh YL, Lin LH. Thrombocytopenic purpura following vaccination in early childhood: experience of a medical center in the past 2 decades. J Chin Med Assoc. 2010;73(12):634–7. doi: 10.1016/S1726-4901(10)70138-6.
  10. Faki Osman ME. Childhood immune thrombocytopenia: Clinical presentation and management. Sudan J Paediatr. 2012;12(1):27–39.
  11. Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2015;2015:237–42. doi: 10.1182/asheducation-2015.1.237.
  12. Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022;76:103820. doi: 10.1016/j.ebiom.2022.103820.
  13. Witmer CM, Lambert MP, O’Brien SH, Neunert C. Multicenter Cohort Study Comparing U.S. Management of Inpatient Pediatric Immune Thrombocytopenia to Current Treatment Guidelines. Pediatr Blood Cancer. 2016;63(7):1227–31. doi: 10.1002/pbc.25961.
  14. Consolini R, Costagliola G, Spatafora D. The Centenary of Immune Thrombocytopenia-Part 2: Revising Diagnostic and Therapeutic Approach. Front Pediatr. 2017;5:179. doi: 10.3389/fped.2017.00179.
  15. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86. doi: 10.1182/blood-2009-06-225565.
  16. Carcao MD, Zipursky A, Butchart S, et al. Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl. 1998;424:71–4. doi: 10.1111/j.1651-2227.1998.tb01239.x.
  17. Matzdorff A, Meyer O, Ostermann H, et al. Immune Thrombocytopenia – Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41(Suppl 5):1–30. doi: 10.1159/000492187.
  18. Terrell DR, Neunert CE, Cooper N, et al. Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. Medicina (Kaunas). 2020;56(12):667. doi: 10.3390/medicina56120667.
  19. Kuhne T, Freedman J, Semple JW, et al. Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura. J Pediatr. 1997;130(1):17–24. doi: 10.1016/S0022-3476(97)70305-6.
  20. Beck CE, Nathan PC, Parkin PC, et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr. 2005;147(4):521–7. doi: 10.1016/j.jpeds.2005.04.032.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2024 Clinical Oncohematology